LIVN

LivaNova PLC 10-Q Summary: Q2 2026

Business Context and Reporting Period

This summary covers LivaNova PLC's unaudited financial results for the quarterly period ended June 30, 2026. LivaNova is a global medical technology company operating in two primary segments: Cardiopulmonary (heart-lung machines, oxygenators) and Neuromodulation (VNS Therapy for epilepsy and depression, and sleep apnea devices). The company is a large accelerated filer listed on Nasdaq (LIVN).

Key Financial Metrics

Margins (YTD 2026): Gross Margin was 68.7%; Operating Margin was 12.1%. The effective tax rate for the six months ended June 30, 2026, was (186.8)% due to discrete tax benefits.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 10.8% in Q2 and 12.5% YTD compared to 2025. Growth was driven by both segments, with Cardiopulmonary up 11.2% (Q2) and Neuromodulation up 10.1% (Q2).
• Profitability Surge: Net income turned significantly positive ($108.6M in Q2) compared to $27.2M in Q2 2025. This is largely attributable to a massive one-time tax benefit of $95.4M recognized in 2026 following an Italian tax ruling on the deductibility of the SNIA environmental liability.
• Debt Reduction: Total debt obligations decreased from $376.7M (Dec 31, 2025) to $293.5M (June 30, 2026). The company fully repaid its Term Facilities ($95.9M) in January 2026.
• Segment Performance:
  • Cardiopulmonary: Q2 segment income decreased 10.4% to $28.2M, primarily due to an $11.4M increase in litigation provisions for the 3T Heater-Cooler device, partially offset by revenue growth and tariff refunds.
  • Neuromodulation: Q2 segment income increased 8.8% to $60.9M, driven by revenue growth.

Guidance, Outlook, Risks, and Unusual Items

• Regulatory Milestone: In March 2026, the FDA granted Premarket Approval (PMA) for the aura6000 System for obstructive sleep apnea (OSA). This triggered a $60.5M contingent consideration payment in June 2026.
• SNIA Environmental Litigation: A current liability of $385.0M remains recorded for the SNIA environmental matter following the Italian Supreme Court decision in March 2025. The case was referred back to the Court of Appeal for implementation of damages; a hearing is scheduled for December 2026 to discuss potential out-of-court resolution.
• Product Liability: Litigation provisions for the 3T Heater-Cooler device increased to $23.1M as of June 30, 2026, reflecting approximately 60 filed and unfiled claims worldwide.
• Derivatives: Significant volatility in foreign exchange and other income/expense ($29.5M expense YTD 2026) was driven by fair value adjustments to the 2029 Embedded Derivative and Capped Calls.
• Outlook: Management believes current liquidity sources (cash and $225M credit facility availability) are sufficient for the next 12 months. No specific forward-looking financial guidance was provided in this text.

Investor Verification Checklist

• Tax Benefit Sustainability: Verify the permanence of the $95.4M discrete tax benefit from the Italian ruling and its impact on future effective tax rates.
• SNIA Liability Resolution: Monitor the December 2026 Court of Appeal hearing regarding the $385M SNIA environmental liability and potential settlement terms.
• 3T Heater-Cooler Litigation: Track the number of new claims and the adequacy of the $23.1M provision against potential future judgments.
• Derivative Exposure: Assess the impact of share price volatility on the fair value of the 2029 Notes embedded derivatives and capped calls, which significantly affect non-operating income.
• Debt Covenant Compliance: Confirm continued compliance with the 2021 First Lien Credit Agreement covenants following the repayment of Term Facilities.